B

Bergenbio ASA
OSE:BGBIO

Watchlist Manager
Bergenbio ASA
OSE:BGBIO
Watchlist
Price: 11.8 NOK -5.9% Market Closed
Market Cap: 479.2m NOK
Have any thoughts about
Bergenbio ASA?
Write Note

Bergenbio ASA
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Bergenbio ASA
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
B
Bergenbio ASA
OSE:BGBIO
Income from Continuing Operations
-kr152.3m
CAGR 3-Years
21%
CAGR 5-Years
5%
CAGR 10-Years
N/A
Hofseth Biocare ASA
OSE:HBC
Income from Continuing Operations
-kr133.5m
CAGR 3-Years
-4%
CAGR 5-Years
-11%
CAGR 10-Years
-12%
L
Lytix Biopharma AS
OSE:LYTIX
Income from Continuing Operations
-kr87.9m
CAGR 3-Years
-28%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
Arcticzymes Technologies ASA
OSE:AZT
Income from Continuing Operations
kr7m
CAGR 3-Years
-53%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
N
Nykode Therapeutics ASA
OSE:NYKD
Income from Continuing Operations
-$37.9m
CAGR 3-Years
N/A
CAGR 5-Years
-50%
CAGR 10-Years
N/A
T
Thor Medical ASA
OSE:TRMED
Income from Continuing Operations
-kr18.7m
CAGR 3-Years
64%
CAGR 5-Years
45%
CAGR 10-Years
7%
No Stocks Found

Bergenbio ASA
Glance View

Market Cap
461.2m NOK
Industry
Biotechnology

BerGenBio ASA engages in the development of biopharmaceutical product for cancer therapy. The company is headquartered in Bergen, Hordaland. The company went IPO on 2017-04-07. The firm's business portfolio comprises such development stage products as oral axillary lymphoscintigraphy (AXL) kinase inhibitors, small molecule AXL inhibitors, and antibody programs. Its flagship product is BGB324, an orally avaliable small molecule AXL kinase inhibitor. Inhibition of AXL kinase activity addresses an important mechanism in the evolution of cancer cell in terms of its aggressiveness, and focuses on creation of therapeutic options for cancer patients. The firm also performs a range of clinical trials for interested patients, primarily affected with acute myeloid leukemia and non-small cell lung cancer.

BGBIO Intrinsic Value
0.2 NOK
Overvaluation 98%
Intrinsic Value
Price
B

See Also

What is Bergenbio ASA's Income from Continuing Operations?
Income from Continuing Operations
-152.3m NOK

Based on the financial report for Sep 30, 2024, Bergenbio ASA's Income from Continuing Operations amounts to -152.3m NOK.

What is Bergenbio ASA's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
5%

Over the last year, the Income from Continuing Operations growth was 33%. The average annual Income from Continuing Operations growth rates for Bergenbio ASA have been 21% over the past three years , 5% over the past five years .

Back to Top